(Q44441275)

3 December 2017

Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial (English)

1 reference

3 December 2017

0 references

1 reference

1 reference

Jean-Charles Schwartz

10

object named as

Jean-Charles Schwartz

0 references

Isabelle Arnulf

object named as

Isabelle Arnulf

4

0 references

Gert Jan Lammers

3

object named as

Gert Jan Lammers

1 reference

3 December 2017

1

Yves Dauvilliers

1 reference

3 December 2017

2

Claudio Bassetti

1 reference

3 December 2017

7

Philippe Lehert

1 reference

3 December 2017

8

Claire-Li Ding

1 reference

3 December 2017

Geert Mayer

5

1 reference

3 December 2017

Andrea Rodenbeck

6

1 reference

3 December 2017

Jeanne-Marie Lecomte

9

1 reference

3 December 2017

HARMONY I study group

11

1 reference

3 December 2017

7 October 2013

1 reference

3 December 2017

1 reference

3 December 2017

12

1 reference

3 December 2017

11

1 reference

3 December 2017

1068-1075

1 reference

Narcolepsy with cataplexy

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Hypocretins (orexins) and sleep-wake disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

EFNS guidelines on management of narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Antidepressant drugs for narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Histaminergic Mechanisms in Brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Histamine in the nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Histamine H3 receptor antagonists go to clinics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

The histamine H3 receptor: from discovery to clinical trials with pitolisant

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970225-4

7 January 2021

10.1016/S1474-4422(13)70225-4

Identifiers

DOI

1 reference

release_7m5jbfib3fcgfjzfbxynpeqcr4

3 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7m5jbfib3fcgfjzfbxynpeqcr4

24 November 2022

mapped directly with Wikidata item

1 reference